The revenue of the women’s healthcare market in 2016 is estimated at $31.1bn and is expected to grow at a CAGR of 3.8% in the first half of the forecast period. Among various segments in the Women’s Healthcare market, the Postmenopausal Osteoporosis segment dominated the Global Women’s Healthcare market with a share of 36.99% in 2016.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 154-page report you will receive 96 charts – all unavailable elsewhere.
The 154-page report provides clear detailed insight into the women’s healthcare market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Women’s Healthcare market forecasts from 2017-2027
• This report also breaks down the revenue forecast and SWOT Analysis for the main submarkets:
• Postmenopausal Osteoporosis
• Hormonal Contraceptives
• Infertility
• Endometriosis
• Polycystic Ovary Syndrome
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US and Latin America
• Japan
• The UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Rest of the World
• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval
• This report also discusses the drivers, challenges and trends that affect the global women’s healthcare market
• Our study discusses the selected leading companies that are the major players in the global women’s healthcare market
• Bayer
• Eli Lilly
• Merck & Co.
• Pfizer
• Sanofi
• Amgen
• Novo Nordisk
• AbbVie
• Bristol-Myers Squibb (BMS)
Visiongain’s study is intended for anyone requiring commercial analyses for the women’s healthcare market. You find data, trends and predictions.
Buy our report today Global Women’s Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the Global Women’s Healthcare Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecasting Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the Woman’s Health Issue
2.1 What are the major women’s health issues?
2.2 What are the causes and risk factors of women’s health issues?
2.2.1 Modern Urbanization
2.2.1.1 Alcohol Intake:
2.2.1.2 Smoking:
2.2.1.3 Unhealthy diet
2.2.2 Social Restriction and Emotional Factors
2.2.3 Pregnancy
2.2.4 Malnutrition
2.2.5 Obesity
2.2.6 Age
2.3 Diagnosis of Women’s Health Issues
2.3.1 Diagnosis of Breast Cancer
2.3.2 Diagnosis of Osteoporosis
2.3.3 Diagnosis of Endometriosis
2.3.4 Diagnosis of polycystic ovary syndrome
2.3.4.1 Ultrasound
2.3.4.2 Hormonal blood tests
2.3.4.3 Other blood tests
2.4 Epidemiology of Women’s diseases
2.4.1 Epidemiology of Postmenopausal Osteoporosis:
2.4.1.1 Projections:
2.4.2 Epidemiology of Infertility in Women:
2.4.3 Epidemiology of Endometriosis:
2.4.4 Epidemiology of polycystic ovary syndrome
2.5 Humanistic and Economic Burden
2.5.1 Mortality
2.5.2 Morbidity
2.5.2.1 Years of Life Lost(YLL)
2.5.2.1.1 Cardiovascular Disease
2.5.2.1.2 Dyslipidaemia
2.5.2.1.3 Hypertension
2.5.2.1.4 Obesity
2.5.2.1.5 Depression
2.5.3 Economic Impact
2.6 Women’s Health Issues: Prevention and Treatment
2.6.1 Lifestyle changes
2.6.2 Pharmacotherapy
2.6.3 Other treatments
3. Introduction to the Global Women Healthcare Market
3.1 Global Women’s Healthcare Market by Application
3.1.1 Postmenopausal Osteoporosis
3.1.2 Hormonal Contraceptives
3.1.3 Menopause
3.1.4 Infertility
3.1.5 Endometriosis
3.1.6 Polycystic Ovary Syndrome
4. Global Women’s Healthcare Market Size and Forecast 2017-2027
4.1 Market Segmentation by Application
4.1.1 Global Postmenopausal Osteoporosis Market
4.1.1.1 Market Overview
4.1.1.2 Market Size and Forecast
4.1.1.3 Competitive Analysis
4.1.1.4 SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market
4.1.2 Global Hormonal Contraceptives Market
4.1.2.1 Market Overview
4.1.2.2 Market Size and Forecast
4.1.2.3 Competitive Analysis
4.1.2.4 SWOT Analysis of the Global Hormonal Contraceptives Market
4.1.3 Global Menopause Market
4.1.3.1 Market Overview
4.1.3.2 Market Size and Forecast
4.1.3.3 Competitive Analysis
4.1.3.4 SWOT Analysis of the Global Menopause Market
4.1.4 Global Infertility Market
4.1.4.1 Market Overview
4.1.4.2 Market Size and Forecast
4.1.4.3 Competitive Analysis
4.1.4.4 SWOT Analysis of Global Infertility Market
4.1.5 Global Endometriosis Market
4.1.5.1 Market Overview
4.1.5.2 Market Size and Forecast
4.1.5.3 Competitive Analysis
4.1.5.4 SWOT Analysis of the Global Endometriosis Market
4.1.6 Global Polycystic Ovary Syndrome Market
4.1.6.1 Market Overview
4.1.6.2 Market Size and Forecast
4.1.6.3 Competitive Analysis
4.1.6.4 SWOT Analysis of Global Polycystic Ovary Syndrome Market
4.2 Leading Women Healthcare Products, 2016
5. Leading National Markets Forecast 2017-2027
5.1 Geographical Breakdown of Global Women’s Healthcare Drugs Market, 2016
5.1 Women’s Healthcare Drugs Market in the US and Latin America, 2016
5.1.1 Market Forecast of the US and Latin America, 2017-2027
5.2 Women’s Healthcare Drugs Market in the EU5, 2016
5.2.1 Market Forecast of the EU5 Countries, 2017-2027
5.2.1.1 The UK
5.2.1.2 Germany
5.2.1.3 France
5.2.1.4 Spain
5.2.1.5 Italy
5.3 Women’s Healthcare Drugs Market in the Rest of Europe, 2016
5.4 Women’s Healthcare Drugs Market in the Japan, 2016
5.5 Women’s Healthcare Drugs Market in the Rest of the World, 2016
6. Global Women’s Healthcare Market Growth Drivers
6.1 Increase in Aging Female Population
6.2 Expected Launch of Promising Pipeline Molecules
6.3 Growing Prevalence of Postmenopausal Osteoporosis
6.4 Introduction of Technologically Advanced Products
7. Global Women’s Healthcare Market Challenges
7.1 Patent Expiry of Major Blockbuster Drugs
7.2 Lack of Effective Treatments
7.3 Threat of Substitution by Alternative Treatment Options
7.4 High Cost of MRT Therapies
8. Global Women’s Healthcare Market Trends
8.1 Rise in Strategic Partnerships
8.2 Awareness Programs and Initiatives
8.3 Paradigm Shift to Non-Hormonal Therapies
9. Pipeline Molecules
10. Leading Companies in the Global Women’s Healthcare Market, 2016
10.1 Bayer
10.1.1 Bayer: Sales by Geography 2016
10.1.2 Presence in the Women’s Healthcare market
10.1.3 SWOT Analysis
10.2 Eli Lily and Company
10.2.1 Eli Lily: Sales by Geography 2016
10.2.2 Collaboration Agreement with Pfizer
10.2.3 SWOT Analysis
10.3 Merck & Co., Inc.
10.3.1 Merck & Co.: Sales by Geography
10.3.2 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Pfizer: Sales by Geography 2016
10.4.2 Collaboration Agreement with Eli Lily and Company
10.4.3 SWOT Analysis
10.5 Novartis
10.5.1 SWOT Analysis
10.6 Sanofi
10.6.1 SWOT Analysis
10.7 Amgen
10.7.1 SWOT Analysis
10.8 Novo Nordisk
10.8.1 SWOT Analysis
10.9 AbbVie
10.9.1 SWOT Analysis
10.10 Bristol-Myers Squibb
10.10.1 SWOT Analysis
10.11 Other Prominent Vendors in Women’s Healthcare Market
11. Conclusions
Appendices
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 Major women’s health issue
Table 2.2 Women’s Health Drugs (Company and Product)
Table 4.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.2 Global Postmenopausal Osteoporosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.3 Global Hormonal Contraceptives Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.4 Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.5 Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.6 Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.7 Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.8 Revenues of the Leading Women Healthcare Products, 2016
Table 5.1 Global Women’s Healthcare Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 5.2 Global Women’s Healthcare Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 Global Women’s Healthcare Drugs Market by Region: AGR (%), 2016-2027
Table 5.4 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Table 5.5 Women’s Healthcare Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.6 Women’s Healthcare Drugs Market Forecast in the EU5 2016-2027: Revenue ($m), Global Market Share (%), EU5 Market Share (%)
Table 5.7 Women’s Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.8 Women’s Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.9 Women’s Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.10 Women’s Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.11 Women’s Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.12 Women’s Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.13 Women’s Healthcare Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.14 Women’s Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.15 Women’s Healthcare Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 9.1: Active Pipeline Molecules under Development for Treating Epilepsy
Table 10.1 Bayer: Overview 2016
Table 10.2 Bayer: Pipeline
Table 10.3 Eli Lilly and Company: Overview 2016
Table 10.4 Merck: Overview 2016
Table 10.5 Pfizer: Overview 2016
Table 10.6 Pfizer: Pipeline
Table 10.7 Novartis: Overview 2016
Table 10.8 Novartis: Pipeline
Table 10.9 Sanofi: Overview 2016
Table 10.10 Amgen: Overview 2016
Table 10.11 Novo Nordisk: Overview 2016
Table 10.12 AbbVie: Overview 2016
Table 10.13 Bristol-Myers Squibb: Overview 2016
Table 10.14 Bristol-Myers Squibb: Overview 2016
List of Figures
Figure 1.1 Global Women's Health Market Segmentation by Application
Figure 2.1 Percentage of Women Affected by Endometriosis
Figure 2.2 DALY’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
Figure 3.1 Global Women’s Health Market Segmentation by Application (%), 2016
Figure 4.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.2 Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (%),2016
Figure 4.3 Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (million), 2016
Figure 4.4 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.5 SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market
Figure 4.6 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.7 SWOT Analysis of the Global Hormonal Contraceptives Market
Figure 4.8 Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.9 SWOT Analysis of the Global Menopause Market
Figure 4.10 Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.11 SWOT Analysis of the Global Infertility Market
Figure 4.12 Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.13 SWOT Analysis of the Global Endometriosis Market
Figure 4.14 Global Polycystic Ovary Syndrome Market by Class of Drugs (%), 2016
Figure 4.15 Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.16 SWOT Analysis of the Global Polycystic Ovary Syndrome Market
Figure 4.17 Market Share (%) of the Leading Women Healthcare Products, 2016
Figure 5.1 Global Women’s Healthcare Drugs Market by Region: Revenue ($m), 2016
Figure 5.2 Global Women’s Healthcare Drugs Market by Region: Market Share (%), 2016
Figure 5.3 Global Women’s Healthcare Drugs Market by Region: AGR 2016-2027 (%)
Figure 5.4 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Figure 5.5 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2016 (%)
Figure 5.6 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2022 (%)
Figure 5.7 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 5.8 Women’s Healthcare
Figure 5.9 Women’s Healthcare Drugs Market in EU5 by Country: Global Market Share (%), 2016
Figure 5.10 Women’s Healthcare Drugs Market in EU5 Countries: EU5 Market Share (%), 2016
Figure 5.11 Women’s Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2016-2027
Figure 5.12 Women’s Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%),2016-2027
Figure 5.13 Women’s Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%),2016-2027
Figure 5.14 Women’s Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%),2016-2027
Figure 5.15 Women’s Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%),2016-2027
Figure 5.16 Women’s Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%),2016-2027
Figure 5.17 Women’s Healthcare Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2016-2027
Figure 5.18 Women’s Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), 2016-2027
Figure 5.19 Women’s Healthcare Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2016-2027
Figure 10.1 Bayer: Sales by Geography (%), 2016
Figure 10.2 Bayer: SWOT Analysis
Figure 10.3 Eli Lilly: Sales by Geography (%), 2016
Figure 10.4 Eli Lilly: SWOT Analysis
Figure 10.5 Merck & Co.: Sales by Geography (%), 2016
Figure 10.6 Merck & Co.: SWOT Analysis
Figure 10.7 Pfizer: Sales by Geography (%), 2016
Figure 10.8 Pfizer: SWOT Analysis
Figure 10.9 Novartis: SWOT Analysis
Figure 10.10 Sanofi: SWOT Analysis
Figure 10.11 Sanofi: SWOT Analysis
Figure 10.12 Novo Nordisk: Sales by Geography (%), 2016
Figure 10.13 AbbVie: SWOT Analysis
Figure 10.14 Bristol-Myers Squibb: SWOT Analysis
Figure 11.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
AbbVie
Actavis
Adamis Pharmaceuticals
Agile Therapeutics
Allergan
Amgen
ANI Pharmaceuticals
Apothecus Pharmaceutical
AstraZeneca
Bayer
Bristol-Myers Squibb (BMS)
Catalysis
Ciba-Geigy
Conceptus
Crinetics Pharmaceuticals Inc.
Dexa Medica Group
EffRX
Eli Lilly
EndoCeutics
Ferring International Center
Ferring Pharmaceuticals
GlaxoSmithKline (GSK)
HLL Lifecare
Janssen
Ligand Pharmaceuticals
Lipocine
Lupin Pharmaceuticals
Mayer Laboratories
Medicines 360
Merck & Co.
Merck KGaA
Merus Labs
Mylan Laboratories
Neurocrine Biosciences
Novartis
Novo Nordisk
OPKO Health
Pantarhei Bioscience B.V.
Pfizer
Radius Health
Samsung Bioepsis
Sandoz
Sanofi
Sanofi Pasteur
Sanofi Synthelabo
Sanofi-Aventis
Tarsa Therapeutics
Teva Pharmaceuticals
Warner Chilcott
List of Organizations Mentioned in the Report
American Society for Reproductive Medicine
Asia-Pacific Council on Contraception (APCOC)
Bill & Melinda Gates Foundation
Bristol-Myers Squibb Foundation
Catholic medical Mission Board (CMMB)
Centers for Disease Control and Prevention (CDC)
Department of Health and Human Services (HHS)
Deutsche Stiftung Weltbevoelkerung (DSW)
European Society of Cardiology (ESC)
International Federation of Gynecology and Obstetrics (FIGO)
International Federation of Pediatric and Adolescent Gynecology (FIGIJ)
International Osteoporosis Foundation (IOF)
International Planned Parenthood Federation (IPPF)
Pan American Health and Education Foundation (PAHEF)
Royal Health Awareness Society
Sanofi Espoir Foundation
The Heart Truth (US)
The National Institute of Health (NIH)
The Office of the Surgeon General (US)
The Women’s Health Initiative (WHI)
USAID
World Endometriosis Research Foundation
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
